ClinicalThought

Share

Program Content

Activities

  • CLL 1L Therapy
    Key Considerations in Selecting Frontline Therapy for Patients With CLL/SLL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 24, 2024

    Expires: April 23, 2025

  • CLL/SLL: 2L Therapy
    Key Considerations in Selecting Second-line Therapy for Patients With CLL/SLL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 15, 2024

    Expires: May 14, 2025

Faculty

cover img faculity

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Leukemia Service
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center/NewYork-Presbyterian
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd.; and Bristol Myers Squibb.

AbbVie Inc.

AstraZeneca

BeiGene, Ltd.

Bristol Myers Squibb

Partners

CLL Society

ProCE Banner